Business Wire
22 Sept 2026, 12:50 UTC · 6w ago
Impact · against what's priced in
MLCO sees a positive catalyst from the successful proof-of-concept study of its Quicksome™ sublingual delivery system. The rapid systemic appearance of USP testosterone validates the core delivery technology, potentially accelerating the path to a commercial product.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
The More Life Company reported that an exploratory eight-participant study showed rapid systemic appearance of USP testosterone using Quicksome™ sublingual delivery.
Newannounced in press release dated 2026-09-22
So whatSuccessful proof-of-concept for sublingual delivery could significantly shorten the R&D timeline for a commercial testosterone product by FY2027.
More positive than 93% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The exploratory study with eight participants demonstrates that the patented Quicksome™ technology achieves rapid systemic delivery of testosterone, providing a critical pharmacokinetic validation for the company's pipeline.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 87% of ticker scores this week
The company announced successful results from a human pharmacokinetic study for its patented delivery technology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
9h ago
—
No price for MLCO right now — the quote feed didn't answer.
MLCO chart →
